Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Net Income: 2020-2025

Historic Net Income for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$16.5 million.

  • Oncology Institute's Net Income fell 242.66% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.3 million, marking a year-over-year increase of 563.11%. This contributed to the annual value of -$64.7 million for FY2024, which is 2215.65% up from last year.
  • Per Oncology Institute's latest filing, its Net Income stood at -$16.5 million for Q3 2025, which was down 242.66% from -$17.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Net Income ranged from a high of $19.3 million in Q1 2022 and a low of -$30.0 million during Q1 2023
  • Its 5-year average for Net Income is -$11.1 million, with a median of -$15.5 million in 2024.
  • In the last 5 years, Oncology Institute's Net Income skyrocketed by 203634.54% in 2022 and then tumbled by 55142.11% in 2023.
  • Oncology Institute's Net Income (Quarter) stood at -$10.2 million in 2021, then fell by 8.38% to -$11.0 million in 2022, then tumbled by 70.38% to -$18.8 million in 2023, then grew by 29.71% to -$13.2 million in 2024, then dropped by 25.2% to -$16.5 million in 2025.
  • Its Net Income was -$16.5 million in Q3 2025, compared to -$17.0 million in Q2 2025 and -$19.6 million in Q1 2025.